Contact Us

Oncolytic Virus Toxicology Study

Oncolytic virus therapies have shown promising efficacy in solid tumors in several clinical trials. Comparing to non-replicating gene virus therapy, such as retrovirus, replicating oncolytic virus can be shed from treatment in patients and transmitted into the environment or healthy people. However, oncolytic virus itself may also induce certain toxicity in vivo. For example, HSV may infect neuron cells and keep a latent status. Vaccinia virus may infect the human reproductive system. Though most of oncolytic viruses have been attenuated by mutations or deletions, the modified viruses may revert to wild type virus and infect normal host tissues. The toxicity of oncolytic virus mainly comes from the virus and/or the expressed transgene and the off-target effects as well. Creative Biolabs has developed various assays to analyze the toxicity of oncolytic virus and the expressed transgene. Our toxicology studies of oncolytic virus include:

Oncolytic Virus Toxicology Study

According to FDA guideline, present regulations require an integrated summary of the toxicologic effects of the pharmaceuticals in animals and in vitro. To support the safety of the proposed clinical investigation of oncolytic virus, specialists in Creative Biolabs will provide a full set of toxicology study in which the nature of virus species, engineered elements, animal model establishment, targeted disease, and administration route are taken into consideration.

Please feel free to contact us for a quote and further discussion with our scientists.

All products and services are for Research Use Only. Not For Clinical Use.

Online Inquiry

Copyright © 2021 Creative Biolabs. All Rights Reserved.